| 1 |
National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease [J].Am J Kidney Dis, 2003, 42(4 Suppl 3): S1-S201.
|
| 2 |
Tentori F. Mineral and bone disorder and outcomes in hemodialysis patients: results from the DOPPS [J]. Semin Dial.2010, 23(1): 10-14.
|
| 3 |
Kong XL, Zhang LX, Zhang L, et al. Mineral and bone disorder in Chinese dialysis patients: a multicenter study [J]. BMC Nephrology. 2012, 13: 116.
|
| 4 |
Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group.KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of Chronic Kidney Disease-Mineral and Bone Disorder(CKD-MBD) [J].Kidney Int. 2009, Suppl 113: S1-S130.
|
| 5 |
Walsh M, Manns BJ, Klarenbach S, et al.The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial [J]. Hemodial Int,2010, 14(2): 174-181.
|
| 6 |
Pierratos A, Ouwendyk M, Francoeur R, et al. Nocturnal hemodialysis: three-year experience [J]. J Am Soc Nephrol. 1998,9(5): 859-868.
|
| 7 |
Ayus JC, Mizani MR, Achinger SG, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study[J]. J Am Soc Nephrol,2005, 16(9):2778-2788.
|
| 8 |
Maduell F, Navarro V, Torregrosa E, et al. Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration[J]. Kidney Int,2003, 64(1): 305-313.
|
| 9 |
Block GA, Raggi P, BellasiA ,et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients[J]. Kidney Int.2007, 71(5): 438-441.
|
| 10 |
方艺, 丁小强, 邹建洲等. 盐酸司维拉姆治疗维持性血液透析患者高磷血症的短期疗效[J]。中华肾脏病杂志. 2012, 28(3):183-188.
|
| 11 |
Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis[J]. Clin J Am Soc Nephrol, 2008, 3(4): 1125 -1130.
|
| 12 |
Delmez J, Block G, Robertson J, et al. A randomized, doubleblind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis[J]. Clin Nephrol,2007, 68(6): 386-391.
|
| 13 |
Hutchison AJ, Laville M, SPD405-313 Lanthanum Study Group. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden[J]. Nephrol Dial Transplant,2008, 23(11): 3677-3684.
|
| 14 |
Spiegel DM, Farmer B, Smits G, Chonchol M. Magnesium carbonate is an effective phos-phate binder for chronic hemodialysis pa-tients: a pilot study[J]. J Ren Nutr,2007, 17(6):416-422.
|
| 15 |
Chen JB, Chiang SS, Chen HC, et al.Efficacy and safety of SBR759, a novel calcium-free, iron ( Ⅲ ) -based phosphate binder, in Asian patients undergoing hemodialysis a 12-week,randomized, open-label, dose-titration study versus sevelamer hydrochloride[J]. Nephrology, 2011, 16( 8) : 743-750.
|
| 16 |
Geisser P, Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease[J].Clin Nephrol,2010 ,74(1):4-11.
|
| 17 |
McIntyre CW, Pai P, Warwick G, et al. Iron-magnesium hydroxycarbonate ( fermagate ) : a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients[J]. Clin J Am Soc Nephrol. 2009, 4( 2 ): 401-409.
|
| 18 |
Eto N, MiyataY, Ohno H, et al. Nicotinamide prevents the development of hyperphophatemia by suppressing intestinal sodium dependent phosphate transporter in rats with adenine induced renal failure[J]. Nephrol Dial Transplant. 2005, 20(7):1378-1384.
|
| 19 |
Sampathkumar K, Sooraj YS, Ajeshkumar RP, et al. Extended Release nicotinic acid is a promising agent for phosphate control in hemodialysis [J]. Kidney Int. 2006, 69(7): 1281.
|
| 20 |
Kurihara S, Tsuruta Y, Akizawa T, et al. Effect of MCI-196(colestilan) as a phosphate binder on hyperphosphataemia in aemodialysis patients: a double-blind, placebo-controlled, shortterm trial [J]. Nephrol Dial Transplant, 2005, 20( 2): 424 -430.
|
| 21 |
程叙扬, 甘红兵, 吕继成等. 药用活性炭有效降低顽固性高磷血症透析患者血磷水平与钙磷乘积 [J]. 中华肾脏病杂志.2012, 28(1): 21-24.
|
| 22 |
Sprague SM, Llach F, Amdaid M. Paricalcitsl versus calcitriol in the treatment of secondary hyperparathymidism [J]. Kidney Int,2003, 63(4): 1483-1490.
|
| 23 |
Hayashi M, TsuehiyaY, ltaya Y, et al. Comparison ofthe effects of ealcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic hemedialysis：a randomized prospective multicentre trial [J]. Nephrol Dial Transplant, 2004, 19(8): 2067-2073.
|
| 24 |
Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy [J]. N Engl J Med, 2003, 349(5): 446-456.
|
| 25 |
Zhang Q, Li M, You L, et al. Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis [J]. PLoS One, 2012, 7(10): e48070.
|
| 26 |
Ureña P, Fouque D, Brunet P, et al. Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients in realworld clinical practice-The ECHO observational study: French experience [J]. Nephrol Ther, 2012, 8(7): 527-533.
|
| 27 |
Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl [J]. Kidney Int, 2005, 67(2): 760-771.
|
| 28 |
Coyne DW. Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease [J]. Nat Clin Pract Nephrol, 2008, 4(7): 364-365.
|
| 29 |
de Francisco AL, Piñera C, Palomar R. Cinacalcet should be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease [J]. Nat Clin Pract Nephrol, 2008, 4(7): 366-367.
|
| 30 |
The EVOLVE Trial Investigators. Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis [J]. N Engl J Med. 2012 , 367(26): 2482-2494.
|
| 31 |
Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study:a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis [J]. Nephrol Dial Transplant, 2011, 26(4): 1327-1339.
|
| 32 |
Shih ML, Duh QY, Hsieh CB, et a1.Total parathyroidectomy without autotransplantation for secondary hyperparathyroidism[J]. World J Surg, 2009, 33(2): 248-254.
|